CWSR
PCRX icon

Chessman Wealth Strategies RIA’s Pacira BioSciences PCRX Stock Holding History

Chessman Wealth Strategies RIA’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-500
Closed -$25K – 128
2018
Q3 		$25K Buy
+500
New +$21.6K 0.02% 84

Other funds holding PCRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Chessman Wealth Strategies RIA's PCRX Position: Q4 2018 in Review

Chessman Wealth Strategies RIA sold out of Pacira BioSciences (PCRX) in Q4 2018, closing a stake of 500 shares — an estimated $25K sold.

Chessman Wealth Strategies RIA first reported a position in PCRX in Q3 2018 and held it in 1 quarter. The position peaked at $25K in Q3 2018. 208 funds tracked by Wall St. Rank hold PCRX as of Q4 2018.

  • Chessman Wealth Strategies RIA reported no remaining Pacira BioSciences position as of Q4 2018 after selling out during the quarter.
  • Chessman Wealth Strategies RIA sold 500 Pacira BioSciences shares in Q4 2018, an estimated $25K.
  • Chessman Wealth Strategies RIA first reported a position in Pacira BioSciences in Q3 2018 and held it in 1 quarter.
  • Chessman Wealth Strategies RIA's Pacira BioSciences position peaked at $25K in Q3 2018.
  • 208 funds tracked by Wall St. Rank held Pacira BioSciences as of Q4 2018.

Based on Chessman Wealth Strategies RIA's 13F filing for Q4 2018, filed 14 Jan 2019.